Standard Biotools (LAB) Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Revenue data on file, last reported at $21.1 million in Q1 2026.

• Revenue for Q1 2026 came in at $21.1 million, up 4.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.3 million (down 3.71% YoY), and the FY2025 annual result was $85.3 million, down 6.24% from the prior year.
• Revenue retreated to $21.1 million in Q1 2026 per LAB's latest filing, from $23.8 million in the prior quarter.
• Over five years, Revenue peaked at $45.5 million in Q1 2024 and troughed at $18.8 million in Q2 2022.
• A 5-year average of $25.0 million and a median of $24.8 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue soared 81.3% in 2024, then tumbled 55.6% in 2025.
• A 5-year view of Revenue shows it stood at $27.0 million in 2022, then gained by 4.32% to $28.2 million in 2023, then retreated by 12.1% to $24.8 million in 2024, then dropped by 3.96% to $23.8 million in 2025, then declined by 11.13% to $21.1 million in 2026.
• Business Quant data shows LAB's Revenue at $21.1 million in Q1 2026, $23.8 million in Q4 2025, and $19.6 million in Q3 2025.